Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc.
1997
n/a
LTM Revenue $9.1M
LTM EBITDA -$3.1M
$60.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Curatis Holding has a last 12-month revenue of $9.1M and a last 12-month EBITDA of -$3.1M.
In the most recent fiscal year, Curatis Holding achieved revenue of n/a and an EBITDA of -$56.8M.
Curatis Holding expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Curatis Holding valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | n/a | n/a | XXX | XXX | XXX |
Gross Profit | n/a | n/a | XXX | XXX | XXX |
Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
EBITDA | -$43.4M | -$56.8M | XXX | XXX | XXX |
EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
Net Profit | -$0.2M | -$39.3M | XXX | XXX | XXX |
Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
Net Debt | $0.3M | $1.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Curatis Holding's stock price is CHF 11 (or $12).
Curatis Holding has current market cap of CHF 52.9M (or $59.8M), and EV of CHF 53.0M (or $60.0M).
See Curatis Holding trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$60.0M | $59.8M | XXX | XXX | XXX | XXX | $-1.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Curatis Holding has market cap of $59.8M and EV of $60.0M.
Curatis Holding's trades at 6.6x LTM EV/Revenue multiple, and -19.5x LTM EBITDA.
Analysts estimate Curatis Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Curatis Holding and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $60.0M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | -1.1x | XXX | XXX | XXX |
P/E | -1.1x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -28.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCuratis Holding's NTM/LTM revenue growth is 125%
Curatis Holding's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $InfinityT for the same period.
Over next 12 months, Curatis Holding's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Curatis Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Curatis Holding and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | n/a | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | 31% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | $InfinityT | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Curatis Holding acquired XXX companies to date.
Last acquisition by Curatis Holding was XXXXXXXX, XXXXX XXXXX XXXXXX . Curatis Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Curatis Holding founded? | Curatis Holding was founded in 1997. |
Where is Curatis Holding headquartered? | Curatis Holding is headquartered in Switzerland. |
Is Curatis Holding publicy listed? | Yes, Curatis Holding is a public company listed on SWX. |
What is the stock symbol of Curatis Holding? | Curatis Holding trades under CURN ticker. |
When did Curatis Holding go public? | Curatis Holding went public in 2022. |
Who are competitors of Curatis Holding? | Similar companies to Curatis Holding include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Curatis Holding? | Curatis Holding's current market cap is $59.8M |
What is the current revenue of Curatis Holding? | Curatis Holding's last 12-month revenue is $9.1M. |
What is the current EBITDA of Curatis Holding? | Curatis Holding's last 12-month EBITDA is -$3.1M. |
What is the current EV/Revenue multiple of Curatis Holding? | Current revenue multiple of Curatis Holding is 6.6x. |
What is the current EV/EBITDA multiple of Curatis Holding? | Current EBITDA multiple of Curatis Holding is -19.5x. |
Is Curatis Holding profitable? | Yes, Curatis Holding is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.